Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Lon S Schneider; Karen S Dagerman; Julian P T Higgins; Rupert McShane

doi:10.1001/archneurol.2011.69

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Lon S Schneider, Karen S Dagerman, Julian P T Higgins, Rupert McShane

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal)

179 Citations (Scopus)

Abstract

We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.

Original language	English
Pages (from-to)	991-8
Number of pages	8
Journal	Archives of Neurology
Volume	68
Issue number	8
DOIs	https://doi.org/10.1001/archneurol.2011.69
Publication status	Published - 2011

Access to Document

10.1001/archneurol.2011.69

Fingerprint Dive into the research topics of 'Lack of evidence for the efficacy of memantine in mild Alzheimer disease'. Together they form a unique fingerprint.

Cite this

@article{3f7b0cdbd06749348ddd454a7fb07c5f,

title = "Lack of evidence for the efficacy of memantine in mild Alzheimer disease",

abstract = "We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.",

author = "Schneider, {Lon S} and Dagerman, {Karen S} and Higgins, {Julian P T} and Rupert McShane",

year = "2011",

doi = "10.1001/archneurol.2011.69",

language = "English",

volume = "68",

pages = "991--8",

journal = "Archives of Neurology",

issn = "1538-3687",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - Lack of evidence for the efficacy of memantine in mild Alzheimer disease

AU - Schneider, Lon S

AU - Dagerman, Karen S

AU - Higgins, Julian P T

AU - McShane, Rupert

PY - 2011

Y1 - 2011

N2 - We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.

AB - We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.

U2 - 10.1001/archneurol.2011.69

DO - 10.1001/archneurol.2011.69

M3 - Article (Academic Journal)

C2 - 21482915

VL - 68

SP - 991

EP - 998

JO - Archives of Neurology

JF - Archives of Neurology

SN - 1538-3687

IS - 8

ER -